Related Experiment Video

Updated: May 8, 2026

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
10:13

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

Forced downregulation of RACK1 inhibits glioma development by suppressing Src/Akt signaling activity

Renjun Peng1, Bing Jiang, Jianrong Ma

  • 1Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha, Hunan 410078, P.R. China.

Oncology Reports
|September 7, 2013
PubMed

Insights

Receptor for activated C-kinase 1 (RACK1) is elevated in glioma and drives tumor growth. Downregulating RACK1 inhibits glioma progression and may offer a new therapeutic target for brain tumors.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Glioma is the most common primary malignant brain tumor.
  • Receptor for activated C-kinase 1 (RACK1) is involved in crucial cellular functions but its role in glioma is unknown.

Purpose of the Study:

  • To investigate the role of RACK1 in glioma development and progression.
  • To explore RACK1 as a potential therapeutic target for glioma.

Main Methods:

  • Compared RACK1 expression in glioma and normal brain tissues/cells.
  • Utilized siRNA to downregulate RACK1 in human glioma cells (U87, CHG-5) and in vivo xenograft models.
  • Assessed cell proliferation, invasion, apoptosis (Bax, Bcl-2 expression), and Src/Akt signaling pathway activity.

Main Results:

  • RACK1 expression is significantly higher in glioma tissues and cell lines, correlating with malignancy.
  • RACK1 downregulation suppressed glioma cell proliferation and invasion, induced apoptosis, and inhibited tumor growth in vivo.
  • RACK1 inhibition reduced Src/Akt signaling pathway activity.

Conclusions:

  • RACK1 plays a critical role in glioma development and progression both in vitro and in vivo.
  • Targeting RACK1, potentially through siRNA-mediated downregulation, shows promise for glioma treatment by suppressing the Src/Akt pathway.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...